Epitestosterone (17alpha-hydroxy-4-androsten-3-one) is a naturally occurring epimer of testosterone. It apparently parallels the formation of testosterone, but on the other hand its concentration is not influenced by exogenous administration of testosterone. This fact creates the basis of the present doping control of testosterone abuse. Epitestosterone can be considered as a weak antiandrogen in the term of displacement of androgen from receptor binding and as an efficient inhibitor of 5 alpha-reductase. Epitestosterone exerts androgen receptor-independent neuroprotective activity in vitro.

Testosterone acetate, a testosterone ester, is an androgen. It is a steroid lipid molecule considered to be practically insoluble (in water) and basic. It is an anabolic steroid and testosterone prodrug. Testosterone acetate has a faster rate of absorption in the body then other esters. In combination with two other testosterone esters, testosterone valerate and testosterone undecanoate, it is a part of Deposterona, an injectable veterinary blend steroid preparation marketed in Mexico. With its blend of slow and fast-acting esters, Deposterona is essentially a low dosed alternative to Sustanon and is used primarily to treat impotence, weakness, fatigue, and hypogonadism in male breeding animals (cows, pigs, canines, and sheep), and also as a general protein-sparing anabolic. Testosterone acetate is classified as a Schedule III drug by the United States Drug Enforcement Agency and is only legal with a prescription due to his potential for misuse and abuse.

Testosterone 3-(O-carboxymethyl)oxime is a structural testosterone derivative, oxime O-ether formed from testosterone and (aminooxy)acetic acid. It was prepared for use in the anabolic steroids detection tests in human. It has been used for the hormonal analysis of sexual dimorphism in the electric fish Apteronotus and also for developing environmental biosensors for the detection of testosterone in water samples.

Fluphenazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Fluphenazine has not been shown effective in the management of behaviorial complications in patients with mental retardation. Fluphenazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.